MT1002 Phase II Study in ACS Patients With PCI
Last updated on July 2021Recruitment
- Recruitment Status
- Active, not recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Acute Coronary Syndrome
- Type
- Interventional
- Phase
- Phase 2
- Design
- Allocation: N/AIntervention Model: Single Group AssignmentIntervention Model Description: Open-Label, Sequential-Dose Escalation/De-escalation TrialMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 75 years
- Gender
- Both males and females
Description
MT1002 is a novel bispecific peptide with properties of a direct thrombin inhibitor and a glycoprotein IIb/IIIa inhibitor. Three doses of MT1002 will be sequentially tested in cohorts of 6 patients each to achieve target ACT.
MT1002 is a novel bispecific peptide with properties of a direct thrombin inhibitor and a glycoprotein IIb/IIIa inhibitor. Three doses of MT1002 will be sequentially tested in cohorts of 6 patients each to achieve target ACT.
Tracking Information
- NCT #
- NCT04723186
- Collaborators
- Not Provided
- Investigators
- Not Provided
Get Well Soon